The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore representing a major target for drug development in this disease. We show here that the specific mTOR kinase inhibitor AZD8055 blocked mTORC1 and mTORC2 signaling in AML. Particularly, AZD8055 fully inhibited multisite eIF4E-binding protein 1 phosphorylation, subsequently blocking protein translation, which was in contrast to the effects of rapamycin. In addition, the mTORC1-dependent PI3K/Akt feedback activation was fully abrogated in AZD8055-treated AML cells. Significantly, AZD8055 decreased AML blast cell proliferation and cell cycle progression, reduced the clonogenic growth of leukemic progenitors and induced caspase-dependent apoptosis in leukemic cells but not in normal immature CD34 þ cells. Interestingly, AZD8055 strongly induced autophagy, which may be either protective or cell death inducing, depending on concentration. Finally, AZD8055 markedly increased the survival of AML transplanted mice through a significant reduction of tumor growth, without apparent toxicity. Our current results strongly suggest that AZD8055 should be tested in AML patients in clinical trials.
INTRODUCTION
The deregulation of signal transduction pathways is a key event in the process of cellular oncogenic transformation. 1 The phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) signaling pathway has been implicated in the biology of many cancer types including acute myeloid leukemia (AML). 2 mTOR is a serine/threonine kinase ubiquitously expressed in mammalian cells. It is now known that mTOR resides in at least two distinctive multi-protein complexes, mTORC1 and mTORC2, which are distinguished by their partner proteins, substrate specificities and sensitivity to rapamycin. 3, 4 mTORC1 is defined as a complex of mTOR and raptor (regulatory-associated protein of mTOR). 5 Rapamycin, through its interaction with the FK506 binding protein 12, disrupts mTORC1 molecular organization and blocks its activity in most cell type. 6 The mTORC1 complex positively regulates protein translation through the phosphorylation of its substrates, ribosomal protein S6 Kinase (P70S6K) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). The role of P70S6K in protein translation is controversial, mostly related to ribosome biogenesis. 7 For 4E-BP1, however, it has been well characterized. Unphosphorylated 4E-BP1 molecules interact with the mRNA cap-binding protein eIF4E and prevent the formation of the translational initiation complex (eIF4F) by sequestering eIF4E in inactive complexes. Upon phosphorylation, 4E-BP1 dissociates from eIF4E, allowing the interaction between eIF4E and eIF4G to occur, which ultimately initiates protein translation. 8 Notably, this active complex preferentially initiates the translation of oncogenic proteins, such as c-Myc, HIF-1, Cyclin D1 or Bcl-xL. 9 The mTORC2 complex is defined by the association of mTOR with rictor (rapamycin insensitive companion of mTOR) and is usually rapamycin-insensitive, 10, 11 although some evidence has suggested that prolonged treatment with rapamycin may inhibit its activity towards the oncogenic kinase Akt, depending on the cell type. 12 Interestingly, mTORC2 has a key role in cell survival and proliferation through its contribution to the full activation of Akt, through the phosphorylation of Akt hydrophobic S 473 residue 13 and is therefore closely connected to the PI3K signaling pathway. Other mTORC2 substrates have been described, such as serum and glucocorticoid protein kinase 1, as well as serum and glucocorticoid protein kinase 1 direct substrate N-Myc downstream regulated gene-1 (NDRG1). 14 Overall, through its participation in both mTORC1 and mTORC2 complexes, the serine/threonine kinase mTOR controls intracellular mechanisms involved in cell growth, proliferation and survival, therefore, representing a target for drug development in oncology. The first generation mTOR inhibitors rapamycin and derivatives (RAD001, CCI-779) have been widely tested as anti-cancer drugs. 3, 4 However, several mechanisms emerged as barriers to their anti-tumor activity and can explain the heterogeneous and mostly disappointing results of clinical trials using those molecules. 15, 16 Recently, we showed that resistance of AML cells to rapamycin is mostly related to a deregulation of protein translation, because of the persistence of highly phosphorylated 4E-BP1 molecules in rapamycin-treated AML cells, 17 leading us and others to design protein translation as a major target for AML therapy. 17 --20 Moreover, rapamycin-induced mTORC1 inhibition stimulates PI3K/Akt activity in primary AML cells through an IGF-1/ IGF-1R autocrine pathway. 21 To alleviate these intrinsic mechanisms of resistance to rapamycin in AML, we tested an mTOR kinase inhibitor, AZD8055 (AstraZeneca, Alderley Park, UK) in human AML cell lines and in primary AML samples, and we demonstrate here for the first time that AZD8055 fully inhibits mTORC1 and mTORC2 activities in those cells. Hence, AZD8055 induces caspasedependent apoptosis and also induces autophagy, resulting in a significant killing of AML cells without affecting the fate of normal CD34 þ hematopoietic progenitors. Moreover, AZD8055 reduces the growth of human AML cells in mice. Given these promising preclinical results, clinical trials with AZD8055 are merited in this setting.
MATERIALS AND METHODS Patients
Bone marrow samples were obtained from 10 patients with newly diagnosed AML (at the exclusion of AML3, AML6 and AML7 phenotypes, see Supplementary 
Cells cultures and reagents
AML blast cells and CD34 þ from three healthy donors were isolated as previously described. 2 The human leukemic cell lines MV4-11 (ref. 22) was cultured in alpha MEM containing 10% FCS. We used, when appropriate, from 1 to 1000 nmol/l AZD8055 (AstraZeneca Cancer & Infection Research Area, Alderley Park, UK), 10 nmol/l rapamycin (Sigma, Saint Louis, MO, USA) and 25 mmol/l LY294002 (Sigma).
RNAi
The transfection of anti-Atg5 and anti-LC3 small interfering RNA in the MV4-11 cell line was performed using Amaxa nucleofector following the manufacturer's instruction (Lonza, Basel, Switzerland), as reported. 17 Whole cell extracts, immunoprecipitation and western blotting Whole cell extracts, immunoprecipitations and western blots were performed as previously described. 17 The images were captured using a CCD camera (LAS3000 from Fujifilm, Tokyo, Japan). The signal intensity was quantified using Multigauge software from Fujifilm. 
Colony assays
The formation erythroid (BFU-E) and granulo-macrophagic (CFU-GM) colony forming units from normal CD34 þ hematopoietic cells and CFU-L assays from primary AML cells, exposed or not to AZD8055, was assessed as reported. 17 Caspase activities measurement AML cells were lysed 30 min at 4 1C in 50 mM HEPES; pH 8; 150 mM NaCl; 20 mM EDTA; 1 mM PMSF; 10 mg/ml leupeptin; 10 mg/ml aprotinin and 0.2% Triton X-100, and lysates were clarified (10 000 g, 15 min, 4 1C). Each assay was done four times, using 50 mg proteins. Cellular extracts were incubated in a 96-well plate, with 0.2 mM Ac-DEVD-AMC (caspase-3 substrate) or Ac-LEHD-AMC (caspase-9 substrate) for various times at 37 1C. Caspase activity was measured by 460 nm OD recording after 390 nm excitation, without or with 1 mM Ac-DEVD-CHO (caspase-3 inhibitor) or 1 mM Ac-LEHD-CHO (caspase-9 inhibitor). Enzyme activities were expressed in arbitrary units per milligrams of protein.
AML xenografts in nude mice
MV4-11 cells were subcutaneously injected in nude mice as previously reported. 22 Mice were first injected with the TMB1 anti-NK antibody 23 to enhance the engraftment of MV4-11, and then treated with 20 mg/kg/day AZD8055 (n ¼ 8) in captisol 30% or with captisol 30% alone (n ¼ 8), given as 200 ml by oral gavages 5 days a week. The tumor growth was measured three times a week. All experiments were conducted in accordance with the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International.
Immunohistochemistry and TUNEL assay
Serial sections in paraffin blocks were stained with anti-phospho-4E-BP1 T 37/46 and S
65
, and anti-Ki67 as previously reported. 22 Apoptosis was assessed by the TUNEL technique, according to the manufacturer's instructions (Roche Applied Science, Penzberg, Germany). The images were obtained using a microscope (DM-2000; Leica, Solms, Germany) equipped with a digital camera (DFC320; Leica) and IM50 4.0 software (Leica).
Statistical analysis
Parametrical variables: data are expressed as mean values and s.d. Statistical significance of differences observed between experimental groups were determined using Student's t-test. Survival experiments: we used log-rank Mantel-Cox and Gehan --Breslow --Wilcoxon tests to compare the survival of mice treated or not with AZD8055. In each case, independent experiments means (i) that the experiments were performed in different days and (ii) that cells from different patients were used.
RESULTS
The specific active-site mTOR inhibitor AZD8055 fully inhibits mTORC1 and mTORC2 signaling in AML cells The biochemical activity of AZD8055 against mTORC1 and mTORC2 was first assessed in the MV4-11 human AML cell line. Concentration-dependent experiments (from 1 to 1000 nmol/l) showed that AZD8055, in contrast to rapamycin, strongly inhibited mTOR S 2481 phosphorylation, which is an autophosphorylation event reflecting the catalytic activity of this kinase. 24 --26 Moreover, P70S6K T 389 phosphorylation, reflecting mTORC1 activity, was as efficiently inhibited with 10 nmol/l AZD8055 than with 10 nmol/l rapamycin or 25 mmol/l LY294002 ( Figure 1a) . Also, the direct mTORC2 substrate Akt S 473 was markedly inhibited by AZD8055 from 10 nmol/l, which was in contrast to the results achieved with rapamycin ( Figure 1a) . Similar results were observed on the indirect mTORC2 substrate NDRG1 T 346 ( Figure 1a ). 12 --14,26 As expected, AZD8055 did not suppress ERK T 202 /Y 204 phosphorylation, in contrast to the specific MEK1/2 (for Mitogen Activated Protein Kinase (MAPK)/Extracellular signal Regulated Kinase (ERK) 1/2) inhibitor UO126, even at the maximal concentration of 1000 nmol/l, strongly arguing against the occurrence of off-target effects (Figure 1a) . Similar results were obtained in the MOLM-14 and OCI-AML3 human AML cell lines (Supplementary Figure S1) . These results emphasize the potential effect of AZD8055 as an mTORC1/2 specific inhibitor in AML.
Similar results were observed in primary AML samples, in which AZD8055 strongly inhibited mTORC1, attested by phospho-P70S6K T 389 inhibition, and mTORC2, reflected by Akt S 473 and NDRG1 T 346 inhibition, without decreasing ERK T 202 /Y 204 phosphorylation (Figure 1b, upper panel) . The quantification of western blot signals obtained from 10 randomly tested primary AML samples showed a decrease of NDRG1 T 346 and P70S6K T 389 of 55%, 83%, 88% and 45%, 85%, 90% when using 10, 100 and 1000 nmol/l AZD8055, respectively, which achieved statistical significance for all concentrations (Figure 1b , lower panel).
AZD8055 blocks protein translation in AML
We recently showed that an important limitation of rapamycin anti-leukemic activity is caused by a sustained oncogenic protein translation, because of the persistence of highly phosphorylated forms of 4E-BP1 molecules in rapamycin-treated AML cells. 17 We thus hypothesized that directly targeting mTOR catalytic activity with AZD8055 could block protein translation more efficiently, resulting in a more potent anti-leukemic activity compared with rapamycin.
We thus compared the effects of rapamycin and AZD8055 on 4E-BP1 phosphorylation in AML cells. In contrast to a standard dose of rapamycin (10 nmol/l) that fully inhibits P70S6K T 389 phosphorylation, AZD8055 induced a dephosphorylation of 4E-BP1 on T 37/46 , S 65 and T 70 residues from 25 nmol/l in the MV4-11 cell line ( Figure 1c ) and also in primary AML samples (Figure 1d, upper panel) , although 4E-BP1 T 70 phosphorylation was reduced only at higher concentration of AZD8055, as reported in other models. 27, 28 Moreover, even higher doses (up to 1000 nmol/l) of rapamycin failed to dephosphorylate 4E-BP1, in contrast to the same concentration of AZD0855 (Supplementary Figure S2) . The quantifications of western blot signals from 10 primary AML samples showed a mean statistically significant decrease of 61%, 94% and 98% of 4E-BP1 S 65 phosphorylation using 10, 100 and 1000 nmol/l AZD8055, respectively (Figure 1d , lower panel).
The phosphorylation of 4E-BP1 is the limiting step in the assembly of the translation initiating complex eIF4F, initiated by the interaction between the eIF4E and eIF4G proteins. 17 We thus performed 7 mGTP pull-down assays in the MV4-11 cell line to study the interaction between eIF4E and eIF4G (active translation) or 4E-BP1 (inactive translation). As shown in Figure 2a , AZD8055 decreased the amounts of eIF4G and increased the amounts of 4E-BP1 associated with eIF4E, switching translation in an inactive state.
We further performed [ 3 H] leucine assays, in which the detection of radioactivity is proportional to the amounts of neosynthesized proteins. AZD8055 markedly decreased the global protein synthesis in the MV4-11 cell line from 100 nmol/l, which closely correlates to the concentration of AZD8055 required to fully inhibit the phosphorylation of 4E-BP1 and to disrupt the interaction between eIF4E and eIF4G (Figure 2b) . 10  1000  500  100  50  25   10  1000  500  100  50  25   ----------+   ---------+  ---------+  -----------+   -------+  ----------+  -AZD10  AZD100  AZD1000  CTR  AZD10  AZD100 Overall, these data demonstrate that AZD8055 is a potent inhibitor of Cap-dependent protein translation, acting through the inhibition of the rapamycin-resistant phosphorylation of 4E-BP1 in AML.
AZD8055 decreases proliferation and cell cycle progression in AML mTOR kinase has been widely implicated in cancer cell proliferation and growth. 3 As AZD8055 emerged from our experiments as a potent mTOR kinase inhibitor blocking both mTORC1 and mTORC2 complexes, we investigated the impact of AZD8055 on the proliferation and the cell cycle in AML.
To determine the cellular proliferation rates, we performed [ 3 H] thymidine pulse assays in seven primary AML samples. We consistently observed a concentration-dependent decrease of cell proliferation, with an IC 50 of 10 nmol/l and a near complete reduction of cell proliferation (decrease of 90% and more of [ Figure S3) . Moreover, the cell cycle analysis using propidium iodide staining showed a significant increase of MV4-11 cells blocked in the G0 --G1 phase of the cell cycle, and a decrease of cells in the S and G2/M phases of the cell cycle upon AZD8055 exposure (Figure 3 , left column). Using a more detailed cell cycle analysis by 7-aminoactinomycin D/Ki67 and phospho-(Ser 10 )-histone H3 staining, as reported, 29 we observed that AZD8055 led to the accumulation of cells in the G0 phase (from 0.8 to 2.3%, 8.2% and 12.5% using 10, 100 or 1000 nmol/l AZD8055, respectively; Figure 3 , middle column) and to a reduction of cells in the M-phase (from 1.67 to 1.35%, 0.37% and 0.25% using 10, 100 or 1000 nmol/l AZD8055, respectively; Figure 3 , right column). Similar results were observed in the MOLM-14 cell line (Supplementary Figure S4) .
Moreover, the clonogenic growth of leukemic progenitors (CFU-L) from primary AML cells incubated with 10 --1000 nmol/l AZD8055 was significantly reduced. The mean decrease of CFU-L was from 60% to 70% with 10 to 1000 nmol/l AZD8055, respectively. In contrast, exposure to AZD8055 barely affected the clonogenic growth and the differentiation of normal CD34 þ hematopoietic progenitors, even at the maximal concentration of 1000 nmol/l. The number of mixed (CFU-GEMM), erythroid (BFU-E) or granulo-monocytic (CFU-GM) colonies was not significantly decreased by AZD8055, compared with the control condition (Supplementary Figure S5) .
AZD8055 induces caspase-dependent apoptosis in AML
We then determined the impact of AZD8055 on AML cells survival. AZD8055 induced an increase in annexin V staining from 14% to 23% and 30% at 24 h and from 16% to 29% and 40% at 48 h when comparing the control condition to 100 and 1000 nmol/l AZD8055, respectively, among seven primary AML samples (Po0.05 for each, Supplementary Figure S6) . Conversely, AZD8055 barely affected the survival of normal immature CD34 þ cells cultured under similar conditions, even at the higher concentration of 1000 nmol/l (Supplementary Figure S6) . We also showed that AZD8055 activated both caspase-3 and caspase-9 in the MV4-11 cell line, in a concentration-dependent manner. This activation was fully reversible by pre-incubation of the cells with the pan-caspase inhibitor Z-VAD (Supplementary Figure S6) .
We concluded from these results that AZD8055 induced caspase-dependent apoptosis in AML cells without affecting the survival of normal immature CD34 þ cells in vitro.
AZD8055-induced cell death of AML cells partly implicates autophagy As mTORC1 controls the activity of key proteins of the autophagy process, such as Atg1/ULK and Atg13, 30 we addressed the question of a possible induction of autophagy by AZD8055, as reported in other cancer cell types. 31 In the MV4-11 cell line, AZD8055 significantly induced an accumulation of the LC3-II form from 10 nmol/l, which reflected autophagy induction, 30 in a similar extent than 10 nmol/l rapamycin. Incubation in an amino-acid deficient medium (EEBS) was used as a control of autophagy induction (Figure 4a ). Autophagy induction by AZD8055 was detected from 1 h incubation and was sustained after 24 h exposure to the drug (Supplementary Figure S7) . Moreover, AZD8055 increased the activity of both cathepsin B and cathepsin L in the MV4-11 cell line, which are endopeptidases activated in lysosomes that indirectly reflect autophagy induction in a timedependent manner 30 (Supplementary Figure S8) . To assess the impact of AZD8055-induced autophagy on AML cell death, we blocked autophagy in the MV4-11 cell line by using small interfering RNAs to knockdown ATG5 or LC3 protein expression. As expected, suppressing ATG5 expression with small interfering RNA impeached AZD8055-induced autophagy, attested by the absence of LC3 II band (Figure 4b, upper panel) . The viability of those small interfering RNA-transfected MV4-11 cells, treated or not with 10 or 100 nmol/l AZD8055, was then quantified by propidium iodide staining and their apoptosis was determined by the activity of caspase-3. Significantly, autophagy blockade increased survival in AML cells treated with 10 nmol/l AZD8055 whereas opposite effects were detected in cells treated with 100 nmol/l AZD8055 (Figure 4b, lower panel) . Moreover, treatment of autophagy-blocked AML cells by the caspase inhibitor Z-VAD did not reverse those results, demonstrating that the effects of Figure S9) .
AZD8055-induced autophagy against AML cells were caspase independent (Supplementary
We concluded from these data that AZD8055 induced autophagy in AML cells, which may be either protective with high dose AZD8055 or implicated in AML cell death when low dose AZD8055 were used. AZD8055 blocks the growth of human AML cells without toxicity in mice We used a xenograft model for AML in nude mice using the MV4-11 leukemic cell line and treated these animals with daily AZD8055 oral gavages. Significantly, AZD8055 reduced the growth of AML tumors (P ¼ 0.009, Figure 5a ). Moreover, AZD8055 significantly improved the survival of mice (P ¼ 0.0058, Figure 5b ) without demonstrating any apparent systemic toxicity, as assessed by daily examination of animals and by routine blood tests for liver (ASAT, ALAT and bilirubine) and kidney (creatinine) functions (Supplementary Figure S10) . As expected, we observed a blockade of mTOR signaling by AZD8055 within tumors, as shown by a near complete inhibition of 4E-BP1 phosphorylation (T 37/46 and S 65 ) in paraffin sections of AML tumors in the AZD8055-treated group (Figure 5c ). We further demonstrated that AZD8055 induced a cell-cycle blockade, as shown by a decrease in Ki67 staining (Figure 5c ), and apoptosis induction, as demonstrated by an increase in TUNEL-stained positive cells, in AZD8055-treated mice (Figure 5d ). These findings demonstrate that AZD8055 markedly represses the growth of AML cells in vivo at well-tolerated doses.
DISCUSSION
The evolution of AML is frequently fatal despite intensive therapies and new therapeutic approaches are urgently needed. The role of the mTOR serine/threonine kinase is crucial in the control of cell proliferation and growth and its activity appears to be consistently enhanced in cancer cells. Recent work emphasized the increased potential of mTOR kinase inhibitors, targeting both mTORC1 and mTORC2 activities, compared with the allosteric mTOR inhibitor rapamycin or its derivatives (RAD001, CCI-779). 26,28,32 --35 We report here for the first time in AML that AZD8055, a specific mTOR kinase inhibitor currently under clinical development, strongly inhibits mTOR kinase activity from low nanomolar concentrations, therefore blocking both mTORC1 and mTORC2 complexes in AML cells in vitro. The biochemical activity of AZD8055 appears more interesting than that of rapamycin, which blocks only partly mTORC1 activity, 15 for its development as anticancer drug.
The PI3K/Akt and mTOR signaling pathways are closely interconnected in most models including in AML. We and others reported that rapamycin-induced mTORC1 inhibition activates a feedback loop towards PI3K/Akt 21 or extracellular signal regulated kinase/mitogen activated protein kinase, 36 which may limit the anticancer activity of rapamycin and conversely, mTORC1 activity reduces PI3K/Akt activation through an S6K-dependent mechanism. 37 Importantly, we show here that mTORC1 inhibition by AZD8055 did not induce extracellular signal regulated kinase/ mitogen activated protein kinase activation in AML cells, in contrast to the results obtained with rapamycin in other cancer models. 36, 38 Moreover, given that Akt S 473 is a direct substrate of mTORC2, which is essential to the full activation of this kinase downstream of PI3K, 13 the blockade of mTORC2 by AZD8055 prevented the phosphorylation of Akt S 473 . In addition, AZD8055 also decreased in parallel the PI3K-dependent Akt T 308 phosphorylation (data not shown). We could hypothesize that AZD8055 induced off-target effects against PI3K, but in vitro experiments clearly established the specificity of this molecule against mTOR, and in particular the fact that it did not target class IA PI3K in vitro. 39 We may also hypothesize that mTORC2-dependent Akt S 473 phosphorylation is essential to the subsequent PI3K/PDK1-dependent phosphorylation of Akt on the T 308 residue, 14, 26 acting as a priming phosphorylation event in contrast to the most currently accepted model. 40 Alternatively, mTORC2 inhibition by AZD8055 may disrupt the Akt kinase activity without affecting PI3K activity, which may cause a transient decrease in Akt T 308 phosphorylation, as reported. 27 An important issue is the comparison between selective mTOR kinase inhibitors, such as AZD8055, and dual PI3K/mTOR inhibitors, such as BEZ235. 29 Indeed, even if the anti-leukemic activity of these two distinct families of molecules appears similar, a complete inhibition of PI3K may not be neutral. Besides their role in Akt activation, classes IA PI3K isoforms display multiple cellular functions through the generation of lipid signals, the phosphoinositides phosphates. 41 Janes et al. 33 recently emphasized the more pronounced immunosuppressive activity of the dual PI3K/mTOR inhibitor PI-103, when compared with the pure catalytic mTOR inhibitor PP242, both in vitro and in vivo in mice. Overall, selectively targeting mTOR may represent an advantage in the clinical practice, particularly in immunocompromised patients, although this hypothesis should be validated by extensively studying the immune system of patients treated with those new molecules in clinical trials.
Interestingly, in contrast to rapamycin, AZD8055 inhibited the phosphorylation of the translation regulator 4E-BP1. Indeed, we recently showed that a major limitation of rapamycin activity is the persistence of highly phosphorylated 4E-BP1 molecules in rapamycin-treated AML cells, allowing efficient protein translation. 17 Thus, through the accumulation of unphosphorylated 4E-BP1 molecules, AZD8055 distorted the balance between translation regulating molecules toward an increase of inactive eIF4E/4E-BP1 complexes, thereby decreasing the global protein synthesis rate. Figure 4 . mTOR-dependent autophagy is implicated in AZD8055-induced AML cell death. (a) The MV4-11 cell line was cultured 12 and 24 h in 10% FCS MEM without or with 10 nmol/l rapamycin (R) and 10, 50 or 100 nmol/l AZD8055 and also in amino-acid deficient EEBS medium (Sigma-Aldrich) as a control of autophagy induction. Autophagy was detected by western blot using anti-LC3 antibody. (b) Upper: the MV4-11 cell line was transfected with anti-Atg5 or anti-LC3 small interfering RNA (siRNA) using Amaxa nucleofector. Cells were then cultured without or with 10 or 100 nmol/l AZD8055 and western blot were done to verify Atg5 and LC3 knockdown, respectively. Lower: viability was assessed by propidium iodide staining and caspase-3 activity was measured in MV4-11 cells transfected or not with anti-Atg5 or anti-LC3 siRNA, treated or not with 10 or 100 nmol/l AZD8055. The histograms represent the mean of three independent experiments. *Po0.05.
Consistent with its biochemical activity, AZD8055 significantly decreased AML cell proliferation and cell cycle progression, and reduced the clonogenic growth of leukemic progenitors although sparing the clonogenic and differentiation potential of normal immature CD34 þ progenitors in vitro, which is in agreement with the effects of OSI-027, another novel specific mTOR kinase inhibitor, in AML. 42 In contrast to rapamycin, 17 AZD8055 also induced a significant caspase-dependent apoptosis in AML cells without affecting the survival of normal CD34 þ cells, which suggested a favorable therapeutic index for this molecule in the hematopoietic system. Interestingly, AZD8055 induced autophagy in AML cells, as rapamycin did, which has been reported in other models. 31 Indeed, mTOR is critical for pre-autophagosomes formation through the activation of Atg proteins. 30 However, the exact role of autophagy in the programmed cell death process is still under debate. Although autophagy may induce cell death in certain conditions, its main role is to maintain cancer cells viability under long-term metabolic stress conditions, this process is referred to as protective autophagy. 43 Quite surprisingly, we observed a bivalent effect of AZD8055 towards autophagy in vitro in AML. At low concentrations (10 nmol/l), AZD8055-induced autophagy significantly participated to AML cell death but conversely, autophagy induced by higher doses of AZD8055 (100 nmol/l) protected AML cells from extensive cell death, and we assume that the main mechanism of AML cell death using higher doses (100 nmol/l) of AZD8055 is caspase-dependent apoptosis. As protective autophagy may be induced in response to chemotherapy, 44 synergistic combinations of chemotherapy with low-dose AZD8055 could be investigated in AML. In contrast, combination of high-doses AZD8055 and autophagy inhibitors, such as chloroquine, 45 may also represent an interesting therapeutic strategy in AML.
In agreement with our in vitro findings, AZD8055 strongly reduced the occurrence of xenografted AML tumors in nude mice and increased the survival of the animals, which was correlated to mTOR inhibition and apoptosis induction detected in tumor samples. These results emphasized the anti-tumor potential of AZD8055 through mTOR inhibition in vivo.
Taken together, our current results highlight the role of mTOR in the biology of AML and strongly support the investigation of the potential of AZD8055 to treat AML patients in clinical trials.
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